Ubrogepant - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for ubrogepant and what is the scope of patent protection?
Ubrogepant
is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Ubrogepant has ninety patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for ubrogepant
| International Patents: | 90 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 24 |
| Clinical Trials: | 11 |
| Patent Applications: | 146 |
| What excipients (inactive ingredients) are in ubrogepant? | ubrogepant excipients list |
| DailyMed Link: | ubrogepant at DailyMed |
Recent Clinical Trials for ubrogepant
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 4 |
| Chicago Headache Center & Research Institute | Phase 4 |
| Allergan | Phase 4 |
US Patents and Regulatory Information for ubrogepant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ubrogepant
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Russian Federation | 2019123406 | ТЕХНОЛОГИЯ ПРИГОТОВЛЕНИЯ ТАБЛЕТОК ДЛЯ CGRP-АКТИВНЫХ СОЕДИНЕНИЙ | See Plans and Pricing |
| Mexico | 2016010169 | FORMULACION DE TABLETA PARA COMPUESTOS ACTIVOS DE PEPTIDO RELACIONADO CON EL GEN DE CALCITONINA. (TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS.) | See Plans and Pricing |
| European Patent Office | 2638042 | DÉRIVÉS DE PIPÉRIDINONE CARBOXAMIDE AZAINDANE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CGRP (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS) | See Plans and Pricing |
| Eurasian Patent Organization | 022850 | ПИПЕРИДИНОНКАРБОКСАМИДАЗАИНДАНЫ - АНТАГОНИСТЫ РЕЦЕПТОРА CGRP (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS) | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2015119924 | See Plans and Pricing | |
| South Korea | 20220136460 | CGRP-활성 화합물에 대한 정제 제제 (CGRP- TABLET FORMULATION FOR CGRP-ACTIVE COMPOUNDS) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
